Lv3
294 积分 2023-09-26 加入
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
13天前
已完结
The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States
27天前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
4个月前
已完结
Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions
4个月前
已完结
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma
4个月前
已完结
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study
4个月前
已关闭
Emerging evidence for adapting radiotherapy to immunotherapy
4个月前
已完结
Real-World Patient Characteristics and Time on Treatment Outcomes Among Patients Receiving First-Line Pembrolizumab in the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the United States
5个月前
已关闭
Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma
5个月前
已完结
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions
5个月前
已完结
皖公网安备34019202002308
